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Strengths and limitations of this study
 ► Surveys of multidisciplinary healthcare profession-
als identified the need for an online resource dedi-
cated to severe asthma.
 ► This report describes the development of a novel 
website resource designed to increase awareness 
of severe asthma, provide evidence- based resourc-
es and support healthcare professionals.
 ► Written and visual content was developed by an in-
ternational team of experts and underwent detailed 
internal review and approvals.
 ► User feedback from a diverse range of stakeholders 
was incorporated to enhance website functionality 
and clinical utility.
 ► Additional research is required to demonstrate the 
effects of the resource on clinician practice and pa-
tient outcomes.
AbStrACt
Objectives Severe asthma imposes a significant burden 
on individuals, families and the healthcare system. New 
treatment and management approaches are emerging 
as effective options for severe asthma. Translating new 
knowledge to multidisciplinary healthcare professionals 
is a priority. We developed ‘The Severe Asthma Toolkit’ 
(https:// toolkit. severeasthma. org. au) to increase 
awareness of severe asthma, provide evidence- based 
resources and support decisionmaking by healthcare 
providers.
Setting Roundtable discussions and a survey of 
Australians clinicians were conducted to determine 
clinician preferences, format and content for a severe 
asthma resource.
Participants A reference group from stakeholder and 
consumer bodies and severe asthma experts provided 
advice and feedback. A multidisciplinary team of 
international experts was engaged to develop content. 
Written content was based on up- to- date literature. Peer 
and editorial review were performed to finalise content 
and inform web design. Website design focused on user 
experience, navigation, engagement, interactivity and 
tailoring of content for a clinical audience.
results A web- based resource was developed. 
Roundtable discussions and a needs assessment 
survey identified the need for dedicated severe asthma 
management resources to support skills training. The 
end- product, which launched 26 March 2018, includes an 
overview of severe asthma, diagnosis and assessment, 
management, medications, comorbidities, living with 
severe asthma, establishing a clinic, paediatrics/
adolescents and clinical resources. Analytics indicate 
access by users worldwide (32 169 users from 169 
countries). User survey results (n=394) confirm access 
by the target audience (72% health professionals), who 
agreed the toolkit increased their knowledge (73%) and 
confidence in managing severe asthma (66%), and 75% 
are likely to use the resource in clinic.
Conclusions The Severe Asthma Toolkit is a unique, 
evidence- based internet resource to support healthcare 
professionals providing optimal care for people with severe 
asthma. It is a comprehensive, accessible and independent 
resource developed by leading severe asthma experts to 
improve clinician knowledge and skills in severe asthma 
management.
IntrOduCtIOn
Asthma is a common disease, affecting over 
330 million people worldwide.1 Over the last 
30 years, there have been significant advances 
in asthma management both in terms of phar-
macotherapy and self- management initia-
tives, resulting in improved outcomes for 
patients including reduced asthma mortality. 
However, approximately 3%–10% of people 
with asthma have severe treatmentrefractory 
disease, which fails to respond to standard 
therapies despite confirmation of diagnosis, 
management of common problems such as 
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poor adherence and treatment of comorbidities, and 
outcomes for this population are poor.2 3 People with 
severe asthma experience significant and additional 
disease burden compared with individuals with mild- 
to- moderate asthma, including ongoing uncontrolled 
symptoms,4 impaired quality of life,5 6 frequent attacks, 
hospitalisations7 and early death.8 Severe asthma also 
places a substantial financial burden on affected individ-
uals and society.9 10
With the recognition that severe asthma is different 
from mild- to- moderate disease, and has unique diag-
nostic, assessment and management requirements, new 
approaches to pharmacotherapy and disease manage-
ment are emerging.8 These include an increasing 
number of novel treatment options for people with severe 
disease, such as monoclonal antibody therapies, which 
require measurement of biomarkers to identify those 
patients most likely to respond to therapies targeted to, 
at this stage, ‘T2 high’ asthma inflammatory pathways.11 
While these treatments are revolutionising severe asthma 
management in terms of improved patient outcomes, 
their implementation into practice requires support; this 
could be in the form of new resources, skills and training 
for clinicians.12 Implementation of approaches to identify 
and manage asthma that is difficult to control because 
of treatable problems and comorbidities is needed.12 
Furthermore, new paradigms for disease management 
are now proposed (eg, ‘treatable traits’),13 14 and there is 
a need for ongoing development of disease and manage-
ment paradigms. At present, our healthcare systems 
are ill- equipped to implement these approaches,15 and 
our multidisciplinary clinician training programmes 
have not yet been redesigned to facilitate training in 
these approaches.12 Furthermore, much of the clinical 
education available relating to asthma focuses on mild- 
to- moderate disease, and this knowledge and training is 
often extrapolated and applied to patients with severe 
disease, for example, a stepwise escalation of anti- 
inflammatory corticosteroid treatment that is appropriate 
for mild- to- moderate disease. This is inappropriate for 
severe asthma, which responds differently to treatment, 
impacts patients in different ways and requires a different 
approach to management (eg, targeted add- on therapy).
Severe asthma resources that have been developed have 
primarily been tailored for a patient audience, providing 
an overview of the topic rather than clinical guidance (eg, 
Asthma Australia, Asthma UK websites and the recently 
launched HealthTalk Australia severe asthma website). 
Specific educational and clinical resources for severe 
asthma are required for health professionals, as we previ-
ously identified in roundtable discussions by a panel of 
severe asthma experts.12 Educational resources to up- skill 
multidisciplinary clinicians and to support management 
where specialist care is limited (eg, rural and remote 
regions) are also needed.12
There is a growing use of online resources in health 
professional education.16 17 E- learning approaches 
enhance and enable flexible learning.17 18 Website- based 
resources provide flexibility in the time and delivery of 
education and are ideally suited for the broad distribu-
tion and delivery of educational materials,17 18 including 
to remote and rural settings. Online resources are also 
easily accessible in clinical settings, providing an opportu-
nity for practical utility to inform practice. To our knowl-
edge, no dedicated educational and training websites 
exist to inform the clinical management of severe asthma.
We proposed that a web- based resource designed for 
clinicians to increase awareness of severe asthma and to 
inform the management of severe asthma was required. 
We developed the Severe Asthma Toolkit website 
(https:// toolkit. severeasthma. org. au)19 to address this 
need. Content is targeted at clinicians in primary and 
specialist care, in both private and public clinic settings. 
The Severe Asthma Toolkit is an educational resource 
providing up- to- date information on topics relevant to 
severe asthma and a practical, evidence- based guide to 
inform disease management. The purpose of this article 
is to describe the processes undertaken in: (1) assessing 
the need for a severe asthma resource, (2) informing the 
content and format, (3) the development process and (4) 
to report data on resource usage and user feedback.
MethOdS
This project was initiated by the Translation Committee of 
the Centre of Excellence in Severe Asthma.20 The Centre 
of Excellence in Severe Asthma (https://www. severe-
asthma. org. au) is a network of Australian researchers 
funded by the Australian National Health and Medicine 
Research Council’s (NHMRC) Centres of Research Excel-
lence programme. The Centre of Excellence was funded 
to generate new knowledge in severe asthma, translate 
research evidence into policy and practice, develop novel 
resources and build clinical workforce capacity. Devel-
opment of the Severe Asthma Toolkit was led by Centre 
of Excellence chief investigators, and all funding for the 
project was provided by the Centre of Excellence.
Conception and project scoping
In December 2015, we hosted a full day of roundtable 
discussions with multidisciplinary experts from a range 
of healthcare disciplines, stakeholder organisations and 
biopharmaceutical industry.12 The aim of this meeting 
was to identify knowledge gaps in severe asthma research 
and practice and to develop consensus on areas for 
improvement.12 Key management gaps were identi-
fied, including limited awareness of severe asthma and 
limited access to high- quality multidisciplinary training 
programmes for clinicians treating patients with severe 
asthma; new resources to assist clinicians in severe asthma 
management were proposed.12 We then carried out a 
needs assessment survey during a Post- Graduate Work-
shop on Severe Asthma held at the 2017 Thoracic Society 
of Australia and New Zealand (TSANZ) Annual Scientific 
Meeting to determine demand for a dedicated severe 
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Figure 1 Overview of content development process and 
governance for the Severe Asthma Toolkit. A flowchart 
illustrating the key steps involved in development of the 
Severe Asthma Toolkit, the contributors involved and their 
areas of contribution. The number of contributors are 
indicated in brackets.
asthma resource and to inform the type and format of 
content.
Patient and public involvement
Content was codesigned with consumer representa-
tives and end- users. A reference group that included 
a consumer advocate, a person with severe asthma and 
members of national consumer organisations, including 
Australia Australia, National Asthma Council Australia 
and the Lung Foundation of Australia was convened. 
Content was reviewed by representatives and amend-
ments made to the content based on the feedback.
Written content development
An overview of the project development process and 
project governance is presented in figure 1. The project 
was overseen by two expert severe asthma clinician 
researchers who led project development, advised and 
reviewed content and provided feedback and editorial 
sign- off prior to publication of any content (Peter G 
Gibson and Vanessa M McDonald). A reference group was 
established, consisting of representatives from peak stake-
holder organisations and consumer groups (including 
representatives from Asthma Australia, TSANZ, National 
Asthma Council and Lung Foundation Australia) and 
multidisciplinary healthcare professionals to provide 
advice and feedback on drafted content and website 
design. The reference group also ensured that materials 
aligned with existing content developed by stakeholder 
organisations and facilitated endorsement by stakeholder 
organisations as relevant.
A writing committee involving a team of multidisci-
plinary clinicians and scientists with relevant expertise 
in severe asthma management was engaged to develop 
content. Core writing group members were assigned to 
lead the development of individual toolkit modules and 
finalised the outline, informed website strategy and drafted 
and reviewed content. Section leads recruited additional 
contributors with necessary expertise to draft subsection 
content with support from the project manager. Contrib-
utors included physicians, nurses, allied health profes-
sionals and scientists with a range of relevant expertise. 
Development was facilitated by a project manager (Steven 
Maltby) who collated initial outlines, developed template 
documents and integrated content based on feedback 
from clinician researchers, coordinated communications 
and provided progress updates. All written content was 
provided pro bono, and no authors had direct links to 
industry/pharmaceutical companies. A full list of contrib-
utors has been provided in online supplementary table 1.
Written content was extensively referenced to peer- 
reviewed literature, with hyperlinks to facilitate access to 
research evidence. Section leads performed peer review 
on modules that they were not involved in drafting. 
Additional editorial review was performed for consis-
tency of message, style and format. Reviewers provided 
specific feedback on drafted content, identified gaps and 
redundant elements and highlighted text that could be 
converted into engaging visual content. All content was 
approved by section leads and the project co- leads prior 
to inclusion on the final website.
Website and audiovisual content development
A web designer (Hyperweb) was employed to develop 
logos, branding and build the website on a WordPress 
content management system. The website was designed 
to emphasise user experience, ease of navigation, 
graphics, engagement, interactivity, visual appeal and the 
amount, type and appropriateness of content. Images, 
videos, graphs and schematics were included to comple-
ment written content and clarify key messages. Visual 
content was developed in consultation with a web devel-
oper, videographer and illustrator. Patient videos were 
provided by content contributors, as acknowledged on 
the toolkit website, with written consent from the patients. 
Linked educational seminars were recorded as part of 
the Centre of Excellence severe asthma seminar series. 
Written consent was provided by participants to share 
seminar videos. Additional images were sourced from 
stock photography websites. Web content was optimised 
for viewing on mobile phones and tablets. Search engine 
optimisation was performed on a page- by- page basis to 
identify relevant search terms and optimise text content.
Prelaunch user feedback
Detailed feedback was sought from core writing and refer-
ence group members (n=22) prior to website launch. Feed-
back was specifically sought on overall impression, user 
experience, visual elements, written content, usefulness 
4 Maltby S, et al. BMJ Open 2020;10:e032877. doi:10.1136/bmjopen-2019-032877
Open access 
Figure 2 Representative figure from the Severe Asthma 
Toolkit. A schematic diagram outlining features of severe 
asthma prevalence and disease burden.
of the resource and gaps before website launch. Feedback 
was incorporated into the final website version.
In addition to user feedback from contributors, poten-
tial users (n=3) were recruited from the backgrounds of 
medicine, nursing and respiratory science prior to the 
website launch to provide feedback on website function-
ality. Users explored the website with minimal direction 
and provided verbal feedback, according to the ‘think- 
aloud’ technique.21 Users were then specifically asked 
about their experience, including overall impression, 
user experience, navigation, graphics, engagement, inter-
activity and the amount and type of content presented. 
Feedback was compiled to inform website design and revi-
sions prior to launch.
Website usage statistics, including number of users/
page- views, user location, time spent on the website and 
navigation behaviour within the website were captured 
using Google Analytics. Video viewing statistics including 
number of views and total view time were captured by 
YouTube analytics.
A pop- up user feedback survey was integrated into 
the website. Respondents were asked about demo-
graphics, how they discovered the website, features they 
were seeking and feedback on content (questions and 
responses are included in online supplementary table 2).
data sharing statement
Data relating to a needs assessment survey, user analytics 
and user feedback surveys are included below. No addi-
tional data are available from this study.
reSultS
establishing the need
The 2015 roundtable discussion, as previously reported,12 
highlighted the need for new resources to inform severe 
asthma management. We conducted a needs assessment 
survey at the 2017 TSANZ Annual Meeting in Canberra 
(Australia), which included a range of healthcare profes-
sionals, including physicians, nurses and allied health 
professionals, with an interest in respiratory disease. 
Respondents were asked ‘do you think there is a need 
for a new resource dedicated to severe asthma’ and ‘what 
formats would be useful to you?’. All respondents (n=24) 
indicated a need for a new resource dedicated to severe 
asthma, with an online/website format (21/24; 88%) 
and interactive modules (15/24; 63%) considered most 
useful. A minority of respondents also indicated that 
brochures (6/24; 25%) and videos (4/24; 17%) would 
be useful. Respondents prioritised practical checklists 
(21/24; 88%), clinic protocols (21/24; 88%), summary 
presentations (18/24; 75%) and literature references 
(15/24; 63%) as useful inclusions in the resource. Respon-
dents also indicated content areas that would be useful 
(eg, dysfunctional breathing, checklists, questionnaires, 
information about monoclonal antibodies and comor-
bidities). Website format and contents were informed by 
these preferences.
Content development
Content was developed in modules to allow users to 
work systematically through a single topic or to navi-
gate directly to specific content. Each toolkit module 
consists of an overview page that supports navigation to 
subpages, which provide in- depth information on each 
topic. Images and schematics are featured throughout to 
clarify content and improve user experience (figure 2). 
A total of 36 videos were embedded in or accessible 
from the website at launch, including an overview of 
the toolkit, educational seminars and patient interviews. 
Modules and subpages are presented in table 1, along 
with a description of the content included. Each module 
focuses on a different topic relevant to severe asthma. A 
‘contact’ page enables user feedback. A legal disclaimer 
is also included to clarify that the website should not be 
relied on by individual patients as a substitute for medical 
advice from healthcare professionals.
Prelaunch user feedback
Feedback obtained prelaunch from reference and writing 
group members and potential users was overall positive 
and provided some ideas for improvement. Reference 
and writing group members provided feedback from a 
range of perspectives, as these groups included repre-
sentatives from stakeholder organisations, consumers 
and multidisciplinary healthcare professionals. Reviewers 
indicated the website was easy to navigate, had engaging 
and useful images and video content and provided educa-
tional content at an appropriate level. Feedback from 
consumer representatives on the reference group empha-
sised the importance of a patient- centred care perspective 
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Table 1 Severe Asthma Toolkit content layout and description
Module Description
About the Severe Asthma Toolkit An introduction to the resource outlining the identified need and included content areas.
What is severe asthma? Information on disease definitions, prevalence, disease burden, pathophysiology, 
symptoms, asthma attacks and phenotypes.
Diagnosis and assessment Outlines the importance of confirming an asthma diagnosis and a practical stepwise 
approach for diagnosis and assessment, including considerations for the use of lung 
function assessments, questionnaires, allergy assessment, phenotyping, bronchoscopy, 
imaging and assessment of occupational asthma.
Management Provides recommendations for an integrated, multidisciplinary approach, including 
content to support asthma education, development of written action plans, reviewing and 
reinforcing self- management skills, multidisciplinary approaches and referral.
Medications Outlines the benefit from a targeted treatment approach, rather than the stepwise approach 
used for mild- to- moderate disease. An overview of reliever, controller and add- on 
therapies, including recommendations for the use of monoclonal antibodies and bronchial 
thermoplasty.
Comorbidities Highlights the importance of considering and systematically assessing comorbidities, 
which contribute to worsened severe asthma outcomes. Content covers pulmonary 
and extrapulmonary comorbidities, including allergic and non- allergic rhinitis, chronic 
rhinosinusitis, dysfunctional breathing, vocal cord dysfunction, chronic obstructive 
pulmonary disease, bronchiectasis, obstructive sleep apnoea, obesity, anxiety and 
depression, gastro- oesophageal reflux disease, osteoporosis and cardiovascular and 
metabolic disease.
Living with severe asthma A patient- centred view of the patient experience including recorded interviews, describing 
daily symptom burden, mental and emotional health, intimacy and relationships, self- 
management support, medication costs, experience of care and attacks and prognosis.
Establishing a clinic Recognising the complexity of organising and delivering care from a dedicated severe 
asthma clinic, content focusses on set- up, staffing and multidisciplinary team approach, 
facilities, delivery approach, tailored referrals, evaluation, opportunities for training and 
research, and barriers and hurdles.
Paediatrics and adolescents Recognising additional considerations for different patient populations, specific content is 
included for paediatrics and adolescents focused on management, assessment, alternative 
diagnosis and comorbidities, psychosocial issues and medications.
Specific populations Material specific for Indigenous Australians and Culturally and Linguistically Diverse 
Backgrounds.
Registries An overview of disease registries and specific details on enrolling patients in current 
Australia severe asthma registries, including the Severe Asthma Web- based Database, 
Australian Mepolizumab Registry and the Australian Xolair Registry.
Resources A range of practical tools for use in clinical practice, including clinic recommendations, 
resources for assessment and systematic and multidimensional assessment, guidance 
for translation and implementation activities, seminar presentations, videos, links and key 
references.
Module subheadings are indicated in italics.
throughout the toolkit, including the use of images with 
diversity in cultural backgrounds and clinical settings, 
and use of ‘lay language’ summaries, where possible. 
Potential users (n=3) provided feedback in interviews on 
website functionality and user experience, agreeing that 
the website was easy to navigate, engaging and educa-
tional. Examples of user quotes included ‘well laid- out’, 
‘helpful resource’, ‘useful format for broad range of audi-
ences’, ‘good balance of graphics/text’, ‘written at an 
accessible level for multiple audiences’ and ‘the project is 
a bold endeavour, which is needed’. Suggested improve-
ments were integrated into the final website design (eg, 
reference hyperlinks, improved patient- centred language 
and representative diversity in images).
The Severe Asthma Toolkit was made available online 
23 March 2018 and officially launched on 26 March at the 
TSANZ Annual Scientific Meeting in Adelaide, Australia. 
From 23 March 2018 to 21 November 2019, 32 169 total 
users accessed the website (42 454 sessions; 99 369 page 
views) from 169 different countries. The most repre-
sented countries are shown in figure 3A. Returning users 
made up 13% of visits (4 182 visitors). Users accessed the 
site via organic searches (eg, Google; 69%), direct links 
(20%), referral from other sites (9%) and social media 
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Figure 3 Severe Asthma Toolkit user access characteristics. Analytics data of: (A) user country and (B) total number of page 
views (n=32 169 users).
Figure 4 User feedback survey responses including 
demographics, website access and feedback. Users 
provided feedback on: (A) position description, (B) age group, 
(C) position title, (D) setting where they interact with patients 
with severe asthma, (E) how they found out about the 
Severe Asthma Toolkit and (F) most useful resources (n=394 
respondents).
(eg, Twitter; 2%). Users accessed the website using a 
range of technologies, including desktop (62%), mobile 
phones (32%) and tablets (6%) and spent an average of 
2 min 27 s on the website per session. The most accessed 
pages are shown in figure 3B. Over the same time period, 
linked and embedded videos were viewed 5 500 times, 
with a total of over 460 hours of viewing time.
Postlaunch user feedback
During the period between 23 March 2018 and 21 
November 2019, 394 website visitors completed the 
on- site user feedback survey. Most identified as health 
professionals (285/394; 72%), working in a respiratory 
(147/394; 37%) or non- respiratory field (138/394; 35%; 
figure 4A). The remaining users included individuals 
with severe asthma or family members (59/394; 15%), 
medical trainees (9/394; 2%), two patient advocates or 
‘other’ (39/394; 10%). Respondents ages ranged: 29% 
were 45–54 years (114/391) and 26% were 55–64 years of 
age (101/391) being the most represented (figure 4B). 
Position titles for respondents that identified as health 
professionals are included in figure 4C. Of note, a large 
proportion of respondents were nursing and allied health 
professionals (52%). The majority of respondents had 
some previous experience with severe asthma manage-
ment (338/376; 90%), either relatively inexperienced 
(132/376; 35%), well experienced (174/376; 46%) or 
expert (32/376; 9%). Respondents interact with patients 
in a range of settings, shown in figure 4D. Respondents 
who answered ‘other’ (n=52), interacted with patients in 
schools/teaching settings (n=13), home visits (n=6) and 
a range of other venues.
Most survey respondents (325/386; 84%) were visiting 
the website for the first time, while 50/386 (13%) had 
visited several times and 11/386 (3%) visit regularly. 
Respondents heard about the website from a range of 
sources shown in figure 4E. Users that responded ‘other’ 
predominantly found out about the website from edito-
rials/newsletters (n=22) and conferences/seminars 
(n=8). Respondents indicated they were seeking each of 
the toolkit topic areas, with most seeking ‘Management’ 
(82%), ‘Medications’ (63%), ‘Diagnosis & Assessment’ 
(62%) and ‘Resources’ (57%). Respondents indicated 
clinic protocols/recommendations as the most useful 
resource on the site (126/368; 34%), along with other 
resources as shown in figure 4F.
Most survey respondents (205/281; 73%) agreed that 
the Severe Asthma Toolkit increased their knowledge of 
severe asthma (figure 5A). The majority also agreed that 
the toolkit improved their confidence in managing severe 
asthma (184/277; 66%; figure 5B), and most agreed 
(195/259; 75%) that they are likely to use this resource in 
the clinic (figure 5C).
dISCuSSIOn
This paper describes the development and user feed-
back of a purpose- built educational resource designed to 
increase awareness of severe asthma and to aid multidis-
ciplinary clinicians in providing evidenced- based contem-
porary care for patients with severe asthma. Our previous 
work indicated that new resources were needed,12 and 
the Severe Asthma Toolkit was developed to address this 
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Figure 5 User survey feedback on resource utility. Users 
provided feedback on whether the Severe Asthma Toolkit 
increased their: (A) knowledge, (B) confidence in managing 
severe asthma and whether they are (C) likely to use the 
resource in the clinic (n=394 survey respondents).
need. To our knowledge, this is the first peer- reviewed 
online severe asthma clinician web- based resource that 
has been developed and that has incorporated the identi-
fied needs of severe asthma clinicians.
Our initial needs assessment confirmed that a dedi-
cated severe asthma resource was required. Living with 
severe asthma has a significant hidden burden, which 
is often under- recognised.22 The Severe Asthma Toolkit 
was developed in part to raise healthcare professionals 
awareness of this disease burden, incorporating patient 
interviews and content on the experience of living with 
severe asthma (eg, ‘Living with Severe Asthma’ module). 
Patients with severe asthma also have unique healthcare 
requirements in terms of self- management needs, treat-
ment approaches and comorbidity management.8 These 
features present unique challenges for clinical manage-
ment and healthcare systems. Knowledge transfer is a 
recognisable challenge in healthcare,23 and in this rapidly 
evolving area of severe asthma management, there was 
a clear need to develop a novel resource to address the 
needs of clinicians and to support education that inte-
grates new management approaches. By presenting both 
educational and practical content, the Severe Asthma 
Toolkit addresses this need.
The value of this resource has been reinforced by the 
uptake and dissemination by stakeholder organisations 
to their respective healthcare professional networks (eg, 
Asthma Australia, TSANZ, National Asthma Council and 
Lung Foundation of Australia) and official recognition of 
the website as a TSANZ- endorsed training resource. The 
TSANZ is the only health peak body representing a range 
of professions (medical specialists, scientists, researchers, 
academics, nurses, physiotherapists and students) across 
various disciplines within respiratory medicine in Australia 
and New Zealand. The current membership of TSANZ is 
~1700, which includes near complete reach to all Austra-
lian respiratory physicians and advanced trainees.
These organisations added links to the toolkit on their 
websites, disseminated details on the resource via email 
lists, advertised the research at training workshops and 
have cited the Severe Asthma Toolkit in their distribu-
tion materials (eg, National Asthma Council ‘Mono-
clonal Antibody Therapy for Severe Asthma’ information 
paper).
To summarise, new management approaches for severe 
asthma require access to healthcare resources. While 
new targeted therapy options are available that provide a 
personalised approach for patients, effective use of these 
treatments requires detailed phenotyping of clinical and 
immunological domains.11 Multidimensional assessment 
and management of comorbidities reduce exacerba-
tions and improve asthma control and asthma- related 
quality of life.24 These approaches require recognition 
of comorbidities, access to multidisciplinary allied health 
professionals and effective coordination of care. Dedi-
cated asthma services also improve healthcare use and 
patient outcomes.25 However, establishment of a severe 
asthma clinic is complex. The Severe Asthma Toolkit 
provides content to support users in each of these issues, 
with evidence- based practical recommendations (eg, 
modules on ‘Asthma Phenotypes’, ‘Phenotyping’, ‘Multi-
dimensional Assessment’ and ‘Establishing a Clinic’) and 
educational infographics (accessible at https:// toolkit. 
severeasthma. org. au/ resources/ infographics/).
Content development and website design were 
informed by a needs assessment, expert opinion and user 
feedback. The result is an online resource that is easy to 
navigate and contains a wide breadth of evidence- based 
content relevant to severe asthma in a single location. 
Google Analytics data identify that users seek and access 
content across all modules of the toolkit. Furthermore, 
the majority of survey respondents indicated that the 
toolkit increased their knowledge and confidence in 
delivering severe asthma management to patients. Impor-
tantly, three quarters of survey respondents indicated they 
will access the resource while seeing patients in the clinic.
Our needs assessment survey indicated that an online 
format would be most useful, among healthcare profes-
sional respondents. Online web formats can be readily 
accessible, free and provide rapid access to evidence- 
based medical information. The Bronchiectasis Toolbox26 
and Australian Asthma Handbook27 are two examples in 
the respiratory field. Clinicians and medical trainees are 
increasingly accessing free online content to comple-
ment existing training programmes.28 User analytics data 
suggest that the Severe Asthma Toolkit is being accessed by 
this intended target audience (72% health professionals) 
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across a range of health disciplines. For context, we note 
that the total membership of the Thoracic Society of 
Australia & New Zealand (the peak professional respira-
tory body in these countries) is approximately 1700 total 
members. Thus, we propose that over 32 000 total users 
accessing the Severe Asthma Toolkit represents signifi-
cant access based on the intended target audience. The 
proportion of nursing and allied health professionals 
accessing the resources was particularly high. While 
the resource has been developed for a healthcare audi-
ence, the online format also provides access to patients, 
supporting additional education opportunities. We 
recognised that accessibility is important, allowing users 
to access from different settings (eg, clinic, home and 
office) and across broad geographical regions, including 
rural and remote regions. The utility and flexibility of this 
format is highlighted by users accessing content using a 
range of devices and from countries around the world, as 
well as survey respondents self- reporting that they would 
use the toolkit as a resource in clinic (75%). Accordingly, 
the website is an accessible resource that provides both 
educational and clinical utility through point- of- care 
access to patient assessment tools, clinical guidelines and 
educational resources.
A further advantage of the online format is the ability 
to include updates. This is particularly relevant in rela-
tion to recent rapid advances in severe asthma treatments 
and management approaches. The website is a live docu-
ment, which allows for the ongoing addition of content 
based on advances in the field. A ‘last updated’ note has 
been added to each web page to provide clarity on when 
content was posted. Development and inclusion of addi-
tional resources will be informed by user feedback to 
ensure that content remains up- to- date and aligns with 
user needs. All revised content will undergo approval by 
the section leads and project co- leads prior to publication.
The cost of creating web resources of this complexity 
can be a significant barrier. The Severe Asthma Toolkit 
was developed for a total cost of approximately $A20 
000. This estimate includes costs for the web developer, 
illustrator, copyright permissions, graphic design, stock 
photography and search engine optimisation. The esti-
mate does not include costs associated with the needs 
assessments, the in- kind support of the contributors, 
project manager or the project leaders, ongoing updates 
or writing costs. Much of these expenses were covered 
by existing Centre of Excellence in Severe Asthma activi-
ties, which is supported by NHMRC Centres of Research 
Excellence grant funding from 2014 to 2019. Centre of 
Excellence funding also supported social media activity 
(Twitter @SevereAsthmaCRE), which was used to increase 
awareness of the Severe Asthma Toolkit and its resources. 
All contributors provided written content and review pro 
bono. Development of this resource would not have been 
possible without their contributions. We do note that 
additional features were considered and not included 
in the resource due to budgetary constraints (eg, func-
tional online forums with question- and- answer capability, 
which would have required dedicated ongoing staffing). 
Basic ongoing maintenance of the website (eg, domain 
registration, web hosting servers and basic software 
updates) are anticipated to be quite minimal ($A1–2000/
year), although dependent on existing staff or volun-
teer contributions. Development of additional resources 
and extensive updates will be dependent on support 
from specific funding (eg, educational grants) or infra-
structure funding. This could include modules targeted 
specifically for a consumer/patient audience, with collab-
orative input from relevant stakeholder organisations. We 
note that a HealthTalk Australia Severe Asthma website 
(https:// healthtalkaustralia. org/ severe- asthma/ over-
view/) was recently launched by Centre of Excellence in 
Severe Asthma Investigators, which presents interviews of 
people living with severe asthma for a public audience.
Our goals for development of this resource were to 
produce a web- based resource that would provide up- to- 
date and disease- specific advice for severe asthma clini-
cians. This has been achieved. In terms of our other 
goals, the results are promising. These aspects included 
promoting awareness of severe asthma; survey respon-
dents indicated that the resource increased knowledge 
(73% of respondents) and confidence (66%) in severe 
asthma management and provides a resource that clini-
cians say they will access while in the clinics seeing patients 
(75%). The toolkit has been accessed by health profes-
sionals engaged in severe asthma (72% of respondents) 
worldwide in 169 different countries, with approximately 
13%–16% of repeat user traffic. We do note that survey 
respondents represent a relatively small proportion of all 
users (394/32 169 = 1.2%), and caution should be used 
in extrapolating these data to the total user population. 
While these data are encouraging, we recognise that 
dissemination is only part of the translation process to 
bring about clinical practice change and improve patient 
outcomes. Further activities are required to translate this 
educational resource to support practice change, and addi-
tional assessment will be required to determine the reach 
of the Severe Asthma Toolkit and its effects on outcomes. 
Additional and ongoing work is now required to increase 
and maintain user traffic, including collaboration with 
stakeholder organisations, linking from contributor web 
pages, social media campaigns (eg, via the Centre of 
Excellence’s Twitter account @SevereAsthmaCRE), work-
shops and professional conferences. The broad exper-
tise of contributors and active engagement with health 
professionals, stakeholders and consumers throughout 
this process were critical to the planning, development 
and current level of dissemination of this website. This 
process was invaluable to identifying the specific needs of 
our target population and is highly recommended for any 
groups looking to develop a similar resource in their area. 
We identified several limitations that we would address if 
we were to develop a new resource. Earlier engagement 
with illustrators and graphic designers would have been 
useful to support further integration of visual and interac-
tive elements. Furthermore, development of informative 
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infographics and handouts summarising evidence from 
the toolkit may be valuable resources to support trans-
lation of evidence into clinical care. While stakeholders 
were actively engaged early in the process to provide 
input, a more thorough communications plan to support 
dissemination of the resource would have been beneficial. 
We are continuing to work on these aspects. This includes 
the development of additional resources, such as clinical 
recommendation documents, infographics, interactive 
case studies and additional content (eg, smoking cessa-
tion and oral corticosteroid treatment). To maximise the 
benefit of this resource, we are continuing to engage with 
other health professionals, including those with limited 
experience in severe asthma management in Australia 
and worldwide.
COnCluSIOn
The Severe Asthma Toolkit was developed in response 
to identified unmet needs to increase awareness of 
severe asthma and support education and training of 
severe asthma multidisciplinary clinicians. The resource 
was developed with input from a range of stakeholders 
and informed by user feedback. The website has been 
accessed by users worldwide. Ongoing evaluation and 
updates to the content will ensure that content remains 
up- to- date and practical. We note that the development 
of the Severe Asthma Toolkit is only one aspect of the 
required implementation approach necessary to support 
healthcare professional awareness and training for severe 
asthma. A concerted effort is now required by all stake-
holders to implement existing evidence and resources 
(including the Severe Asthma Toolkit) to improve clinical 
practice and provide optimal care for people with severe 
asthma.
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